News
Axsome Therapeutics Announces FDA Approval of AXS-07 (meloxicam and rizatriptan)
Axsome Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has approved AXS-07 (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults. This novel oral medication combines meloxicam, a nonsteroidal anti-inflammatory drug, and rizatriptan, a serotonin receptor agonist, to provide rapid and sustained relief from migraine pain.
Advancing Headache Research: Key Priorities for the Next Decade
In a groundbreaking initiative, a multi-stakeholder international group of experts led by the American Headache Society in close collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) and the International Headache Society (IHS), has identified critical research priorities for the headache field.
Pfizer’s zavegepant (ZAVZPRET™) Migraine Nasal Spray Receives FDA Approval
Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults.
Pfizer’s zavegepant (ZAVZPRET™) Migraine Nasal Spray Receives FDA Approval
Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults.
Mentorship Opportunity Available through Headache’s Assistant Editor Program
Headache: The Journal of Head and Face Pain is recruiting a new class of trainees to join its Editorial Board through the Assistant Editor Team Program.
Virtual Issue Summary: Kids (with headache disorders) are not just little adults (with headache disorders)
Headache® has begun to resume the quarterly online release of its virtual issues. Virtual issues can be found at headachejournal.org and represent a carefully curated list of recent publications from the journal
Migraine in the Adolescent Patient Overview
Learn about the diagnosis, symptoms and treatment of migraine specifically for your adolescent patients.
Conducting a Telemedicine Neurologic Examination with Jennifer Robblee, MD
In the video, Dr. Robblee explains telemedicine techniques, gives advice on preparing patients for the appointment and explains how to modify common neurological exam techniques to fit the necessary limitations of telemedicine.
Updated Guidelines for Neuroimaging in Migraine
Researchers update evidence-based recommendations about when to obtain neuroimaging in patients with migraine.
OTC Migraine Treatment: Q&A
Jessica Ailani, MD, FAHS, discusses working with patients and getting honest answers about their OTC migraine treatment strategies
Holistic Migraine Therapies as Integrative Treatment: Q&A with Deena Kuruvilla, MD
Dr. Kuruvilla wants to remind healthcare providers that holistic therapies have a place in migraine treatment, but they should not be trusted as the sole course of action
Study Demonstrates Feasibility of Migraine-Specific CBT
Researchers in Germany showed that targeted behavioral therapies may benefit patients with migraine. Katherine Hamilton, MD, of the University of Pennsylvania, weighs-in on the results of the research.
The Maternal Migraine Link to Babies with Colic to be Unveiled at The American Headache Society 61st Annual Meeting
A leading pediatric headache expert will present data at the American Headache Society (AHS) 61st Annual Scientific Meeting that identifies a connection between mothers with migraine and babies with colic
Recent Developments in Migraine and Cluster Headache Treatment
On June 4, 2019, the FDA approved galcanezumab-gnlm (Emgality®) for the treatment of episodic cluster headache in adults. This self-injection treatment was first approved by the FDA in September 2018 for the preventive treatment of migraine in adults